Nautilus Biotechnology (NAUT) Change in Account Payables (2020 - 2026)
Nautilus Biotechnology's (NAUT) quarterly Change in Account Payables came in at $200000.0 in Q1 2026, up 252.67% year-on-year from $56710.0 in Q1 2025, and up 9900.0% quarter-over-quarter from $2000.0 in Q4 2025.
Nautilus Biotechnology (NAUT) Change in Account Payables (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has disclosed Change in Account Payables across 7 years of filings, most recently posting $200000.0 for Q1 2026.
- Change in Account Payables for Q1 2026 came in at $200000.0, up 252.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $262000.0 (up 132.63% YoY), and the FY2025 annual result was -$69000.0, up 88.06% from the prior year.
- Change in Account Payables came in at $200000.0 for Q1 2026 at Nautilus Biotechnology, up from $2000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $371000.0 in Q4 2023 to a low of -$543000.0 in Q4 2024.
- The 5-year median for Change in Account Payables is $2000.0 (2025), against an average of -$36176.5.
- Across the five-year window, Change in Account Payables plunged 25000.0% in 2022 and surged 252.67% in 2026, its largest moves.
- Nautilus Biotechnology's Change in Account Payables stood at $289000.0 in 2022, then increased by 28.37% to $371000.0 in 2023, then slumped by 246.36% to -$543000.0 in 2024, then jumped by 100.37% to $2000.0 in 2025, then jumped by 9900.0% to $200000.0 in 2026.
- The last three Change in Account Payables figures came in at $200000.0 (Q1 2026), $2000.0 (Q4 2025), and -$20000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | Nautilus Biotechnology | 289.99 Mn | 194.12 Mn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Dec 31, 2024 | -543,000.00 |
| Dec 31, 2024 | -543,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | -402,000.00 |
| Jun 30, 2024 | -402,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Dec 31, 2023 | 371,000.00 |
| Dec 31, 2023 | 371,000.00 |